Today Stories

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advan…

Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA. Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames. The exp…

Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies. Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach. The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development.  CARY, N.C., May 23, 2023 – Global b…

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott's investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the U.S. FDA NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for people…

Tomorrow is #ClinicalTrialsDay 2023, a day dedicated to shining a spotlight on the clinical research community. Organised and promoted by ACRP since 2014, the day is celebrated on May 20th to recognise the day that James Lind started what is considered the first randomised clinical trial on May 20th, 1774. The day presents an opportunity for the community to pause in reflection, recognition, and admiration of all that has been accomplished thanks to clinical trials and the talented professionals driving them. Find out more about how you can get involved in #CTD2023: https://www.clinicaltrialsday.org/getinvolved

Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact MORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer Sozio, SVP Clinical Operations, FSP360, and Caitlin Purinai, Senior Director, Human Resources Business Partner, have been recognized by the Healthcare Businesswomen’s Association (HBA) as admirable female leaders in the healthcare industry. “I am thrilled to see Jennifer Sozio and Caitlin Purinai recognized by the HBA for their outstanding performance and commitment to excellence,” said Michelle Keefe, CEO, Syneos Health. “Jennifer and Caitlin are role models for employees across the organization,…

Company Executives Honored for Notable Biopharmaceutical Industry Impact MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual ELITE Awards. The PM360 ELITE Awards recognize individuals in 19 categories in the life sciences industry who exemplify the following traits: Exceptional Leaders, Innovators, Transformers, and Entrepreneurs (ELITE). Maria Fotiu is honored in the Strategists category for constantly leading her…

Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort  Cambridge, UK, 16th May 2023: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to officially welcome six new ventures to Accelerate@Babraham 2023. Chosen via a rigorous selection process which culminated in short-listed companies being interviewed by representatives of the Babraham Research Campus executive team and all the programme’s strategic partners, the six winning ventures are: Aila Biotech – Co-Founders, James Dooley and Adrian Liston Aila Biotech is developing a unique biologic therapy with promising pre-clinical efficacy in neuroinflammation that has been validated in mult…

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies. WEST JEFFERSON, Ohio, May 15, 2023 (Newswire.com) - AmplifyBio, an emerging hub for the commercialization of advanced therapies, has announced the addition of cell therapy and plasmid manufacturing capabilities to its leading portfolio of preclinical CRO and drug characterization services. The GMP cell therapy and plasmid manufacturing labs, available in South San Francisco, are the latest step in AmplifyBio's broader strategy to build a development environment that de-risks the commercialization of next-generation therapeutics.  AmplifyBio recently acquired from PACT Pharma, Inc, a privately held biopharmaceutical company…

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of the multi-million-dollar corporate initiative ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on…

Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered commercial royalties BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), today announced that they have entered into a strategic collaboration agreeme…

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in…

Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation Net proceeds planned to be redeployed for debt repayment in accordance with Baxter’s stated capital allocation priorities Establishes a diversified, standalone contract development and manufacturing organization (CDMO) platform enhancing healthcare worldwide DEERFIELD Ill. and BOSTON and NEW YORK - 2023-05-08 Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg…

Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and collaborative working space designed specifically to support entrepreneurs focused on developing the next generation of cell and gene therapies / Bayer’s Co.Lab Cambridge co-located with the Bayer Research and Innovation Center (BRIC), BlueRock Therapeutics, and Leaps by Bayer, allowing for direct access to Bayer’s experts / Investment part of Bayer’s continued strategic investment in the U.S. Berlin / Boston-Cambridge, MA, USA, May 5, 2023 – Bayer AG yesterday announced the inauguration of its new life science incubator dubbe…

The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing. The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice. Basel, 4 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and develo…

Enhancing the research and production of drugs in Europe Major investment solidifies Germany’s and Europe’s position as a leading production hub for global medication supply Boehringer Ingelheim breaks ground to build a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. In the presence of German Chancellor Olaf Scholz and Rhineland-Palatinate Minister-President Malu Dreyer, the foundation stone for the major investment of 285 million EUR was laid today. Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultima…

National Biotechnology Company Adds New Location in Louisiana BATON ROUGE, La.--(BUSINESS WIRE)--ImmunoTek Bio Centers opens its 80th and newest ImmunoTek Plasma location in Baton Rouge on Tuesday, May 2, 2023. As the world's largest independent blood and plasma donation center operator, ImmunoTek invites the Baton Rouge community to visit the state-of-the-art facility to learn more about plasma donations and how they can positively impact others. By removing the red and white blood cells from the blood, what remains is the golden liquid called plasma. Blood-plasma helps create medicines and plasma-based therapies that treat patients with various diseases and disorders, including shock and burn patients, bleeding disorders, transplant patients, those suffering from autoimmune diseases, and…

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed Giovanni Caforio, MD, as CEO, Effective November 1, 2023 Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer, effective immediat…

Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared…

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhan…